A Large-Cap Diabetes Stock That’s Growing Like Mad

July 18. 2020. 6 mins read

It’s been quite entertaining lately to watch some Americans waddle around whinging about how oppressed they are, when it’s apparent that none of them have ever visited an actual dictatorship. In many of the 50 remaining dictatorships on this planet, people often starve, yet in the U.S. there seems to be too much food available. While it may not be the most obese country in the world, America still has some pretty portly people. Just over 36% of Americans are obese. Compare that to China’s obesity rate of 6.2%.

Big isn’t beautiful, big puts a tremendous toll on the healthcare system. In 2017, one in every four healthcare dollars was spent on treating people with diabetes. Recent research suggests that obese people are up to 80 times more likely to develop type 2 diabetes than those with a BMI of less than 22. According to the WHO, the worldwide prevalence of obesity nearly tripled between 1975 and 2016. As the world gets fatter and fatter, some companies are making a killing on treating diseases like diabetes. One of those is a life sciences company called Dexcom (DXCM).

The Rapid Rise of Dexcom

Last A

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.